Asset Details
Do you wish to reserve the book?
Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design
Do you wish to request the book?
Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design
2020
Overview
The novel coronavirus whose outbreak took place in December 2019 continues to spread at a rapid rate worldwide. In the absence of an effective vaccine, inhibitor repurposing or de novo drug design may offer a longer-term strategy to combat this and future infections due to similar viruses. Here, we report on detailed classical and mixed-solvent molecular dynamics simulations of the main protease (Mpro) enriched by evolutionary and stability analysis of the protein. The results were compared with those for a highly similar severe acute respiratory syndrome (SARS) Mpro protein. In spite of a high level of sequence similarity, the active sites in both proteins showed major differences in both shape and size, indicating that repurposing SARS drugs for COVID-19 may be futile. Furthermore, analysis of the binding site’s conformational changes during the simulation time indicated its flexibility and plasticity, which dashes hopes for rapid and reliable drug design. Conversely, structural stability of the protein with respect to flexible loop mutations indicated that the virus’ mutability will pose a further challenge to the rational design of small-molecule inhibitors. However, few residues contribute significantly to the protein stability and thus can be considered as key anchoring residues for Mpro inhibitor design.
Publisher
MDPI AG,MDPI
Subject
/ Antiviral Agents - pharmacology
/ Betacoronavirus - drug effects
/ Betacoronavirus - enzymology
/ COVID-19
/ Cysteine Endopeptidases - chemistry
/ Cysteine Endopeptidases - genetics
/ Drug Evaluation, Preclinical
/ Enzymes
/ Genomes
/ Ligands
/ Middle East respiratory syndrome
/ Molecular Dynamics Simulation
/ Mutation
/ Protease Inhibitors - pharmacology
/ Proteins
/ Severe acute respiratory syndrome coronavirus 2
/ Severe acute respiratory syndrome-related coronavirus - enzymology
/ Solvents
/ Viral Nonstructural Proteins - antagonists & inhibitors
/ Viral Nonstructural Proteins - chemistry
/ Viral Nonstructural Proteins - genetics
/ Viruses
